MA38860B1 - Cellule progénitrice immuno-modulatrice (imp) - Google Patents

Cellule progénitrice immuno-modulatrice (imp)

Info

Publication number
MA38860B1
MA38860B1 MA38860A MA38860A MA38860B1 MA 38860 B1 MA38860 B1 MA 38860B1 MA 38860 A MA38860 A MA 38860A MA 38860 A MA38860 A MA 38860A MA 38860 B1 MA38860 B1 MA 38860B1
Authority
MA
Morocco
Prior art keywords
imp
immune
progenitor cell
modulating
modulating progenitor
Prior art date
Application number
MA38860A
Other languages
English (en)
Other versions
MA38860A (fr
Inventor
Ajan Reginald
Martin John Evans
Sabena Sultan
Original Assignee
Cell Therapy Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapy Ltd filed Critical Cell Therapy Ltd
Publication of MA38860A publication Critical patent/MA38860A/fr
Publication of MA38860B1 publication Critical patent/MA38860B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0633—Cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/115—Platelets, megakaryocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)

Abstract

L'invention concerne des cellules progénitrices (imp) immuno-modulatrices et leur utilisation en thérapie.
MA38860A 2014-06-12 2015-06-09 Cellule progénitrice immuno-modulatrice (imp) MA38860B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1410504.3A GB201410504D0 (en) 2014-06-12 2014-06-12 Immuno-modulaltory progenitor (IMP) cell
PCT/GB2015/051673 WO2015189587A1 (fr) 2014-06-12 2015-06-09 Cellule progénitrice immuno-modulatrice (imp)
EP15729886.0A EP2984163B1 (fr) 2014-06-12 2015-06-09 Cellule progénitrice immuno-modulatrice (imp)

Publications (2)

Publication Number Publication Date
MA38860A MA38860A (fr) 2016-02-17
MA38860B1 true MA38860B1 (fr) 2017-09-29

Family

ID=51266501

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38860A MA38860B1 (fr) 2014-06-12 2015-06-09 Cellule progénitrice immuno-modulatrice (imp)

Country Status (23)

Country Link
US (2) US12029763B2 (fr)
EP (2) EP2984163B1 (fr)
JP (2) JP6185657B2 (fr)
KR (2) KR20180004319A (fr)
CN (1) CN105473711A (fr)
AU (1) AU2015273271B2 (fr)
CA (1) CA2951492C (fr)
CY (1) CY1119093T1 (fr)
DK (1) DK2984163T3 (fr)
EA (1) EA034083B1 (fr)
ES (1) ES2622397T3 (fr)
GB (1) GB201410504D0 (fr)
HR (1) HRP20170657T1 (fr)
HU (1) HUE033392T2 (fr)
IL (2) IL249298B (fr)
LT (1) LT2984163T (fr)
MA (1) MA38860B1 (fr)
MY (1) MY181994A (fr)
PL (1) PL2984163T3 (fr)
PT (1) PT2984163T (fr)
SG (1) SG11201610355PA (fr)
WO (1) WO2015189587A1 (fr)
ZA (1) ZA201608402B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201513996D0 (en) * 2015-08-07 2015-09-23 Cell Therapy Ltd Immuno-oncology mesodermal progenitor (IOMP) cell
WO2017168170A1 (fr) * 2016-03-31 2017-10-05 Cell Therapy Limited Cellule progénitrice immunomodulatrice (imp) exprimant un ou plusieurs lymphocytes parmi les lymphocytes cd3, cd3e, cd8, cd8b, cd4, cd5, cd6 et cd7
JP7108537B2 (ja) * 2016-04-27 2022-07-28 ロート製薬株式会社 Ｃｄ２０１、ｃｄ４６、ｃｄ５６、ｃｄ１４７及びｃｄ１６５からなる群より選択される少なくとも１種の細胞表面マーカーを発現する間葉系幹細胞及びその調製方法、並びに上記間葉系幹細胞を含む医薬組成物及びその調製方法
CN106267161A (zh) * 2016-09-30 2017-01-04 广州赛莱拉干细胞科技股份有限公司 一种干细胞制剂及其制备方法和应用
CN107184602B (zh) * 2017-06-01 2020-06-30 刘未斌 一种治疗肿瘤的药物组合
JP7333607B2 (ja) * 2017-07-13 2023-08-25 国立大学法人 東京医科歯科大学 三次元メカノシグナル細胞培養系を用いて作製した腱／靱帯様人工組織
AU2018300272B2 (en) * 2017-07-14 2024-09-19 Orbsen Therapeutics Limited CD39 stromal stem cells methods of isolation and use
CN108660203A (zh) * 2018-05-18 2018-10-16 大连医科大学附属第医院 Cxcr2基因在心脏相关疾病中的用途
EP3805258A4 (fr) * 2018-05-30 2022-06-22 Genome and Company Composition pharmaceutique permettant de prévenir ou de traiter le cancer contenant un inhibiteur de cd300e en tant que principe actif
KR20250160527A (ko) * 2018-06-05 2025-11-13 메디포스트(주) 히알루론산과 줄기세포를 포함하는 연골손상 관련 질환 치료용 약학 조성물
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
GB201900554D0 (en) 2019-01-15 2019-03-06 Cell Therapy Ltd Mesodermal killer (mk) cell
EP3911733B1 (fr) * 2019-01-15 2024-08-21 Cell Therapy Limited Cellule tueuse mésodermique (mk)
CN110314173A (zh) * 2019-07-17 2019-10-11 中国医科大学附属第一医院 一种用于治疗骨关节炎的细胞制剂及其制备方法
WO2021092564A1 (fr) * 2019-11-07 2021-05-14 Massachusetts Eye And Ear Infirmary Transplantation de cellules épithéliales limbiques autologues cultivées (calec)
CN116482350B (zh) * 2022-01-17 2025-10-21 上海源奇生物医药科技有限公司 用于监测急性b淋巴细胞白血病微小残留病灶的流式细胞术试剂盒及监测方法
WO2024080661A1 (fr) * 2022-10-12 2024-04-18 (주) 엘피스셀테라퓨틱스 Nouvelle cellule souche angiogénique
CN120379687A (zh) * 2022-10-14 2025-07-25 爱尔兰国立科克大学 胎盘表达的蛋白用于治疗肌腱损伤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8801537D0 (sv) 1988-04-26 1988-04-26 Ellco Food Ab Cellodlingsmedium samt forfarande for dess framstellning
US8663987B2 (en) 2008-05-28 2014-03-04 Ramot At Tel-Aviv University Ltd. Mesenchymal stem cells for the treatment of CNS diseases
US20120269779A1 (en) 2009-10-30 2012-10-25 Allocure, Inc. Mesenchymal stromal cell populations and methods of using same
EP2506867B1 (fr) * 2009-12-02 2014-10-08 Cardio3 Biosciences S.A. Compositions pharmaceutiques pour la stimulation des cellules souches
US20130189741A1 (en) * 2009-12-07 2013-07-25 Cellscript, Inc. Compositions and methods for reprogramming mammalian cells
WO2012052911A1 (fr) 2010-10-22 2012-04-26 Nokia Corporation Procédé et appareil de réception coopérative pour fonctionnement dispositif à dispositif géré par réseau
LT2729562T (lt) * 2011-07-06 2018-07-25 Cell Therapy Limited Mezodermos ląstelių linijos kamieninės ląstelės
AU2012342218B2 (en) 2011-11-23 2017-03-02 Cell Therapy Limited Platelet lysate gel
US9682104B2 (en) * 2012-01-26 2017-06-20 Jadi Cell Llc Lyophilized platelet lysates
US9670457B2 (en) 2012-05-08 2017-06-06 Stem Cell Reserve Lp Stem cells and matrix from cord tissue

Also Published As

Publication number Publication date
US12029763B2 (en) 2024-07-09
ZA201608402B (en) 2019-04-24
CA2951492C (fr) 2022-12-06
HK1219504A1 (en) 2017-04-07
EP2984163A1 (fr) 2016-02-17
HUE033392T2 (en) 2017-12-28
EP2984163B1 (fr) 2017-02-01
IL249298B (en) 2018-11-29
CY1119093T1 (el) 2018-01-10
LT2984163T (lt) 2017-05-10
AU2015273271A1 (en) 2016-12-22
DK2984163T3 (en) 2017-05-08
AU2015273271B2 (en) 2020-12-17
IL262827A (en) 2018-12-31
HRP20170657T1 (hr) 2017-06-30
NZ727129A (en) 2021-02-26
WO2015189587A1 (fr) 2015-12-17
ES2622397T3 (es) 2017-07-06
KR20180004319A (ko) 2018-01-10
PT2984163T (pt) 2017-05-09
CA2951492A1 (fr) 2015-12-17
JP2016525342A (ja) 2016-08-25
IL249298A0 (en) 2017-02-28
EA201692254A1 (ru) 2017-06-30
JP2017200474A (ja) 2017-11-09
JP6185657B2 (ja) 2017-08-23
CN105473711A (zh) 2016-04-06
PL2984163T3 (pl) 2017-08-31
EP3211069A1 (fr) 2017-08-30
EA034083B1 (ru) 2019-12-25
US20190142869A1 (en) 2019-05-16
US20170080029A1 (en) 2017-03-23
MY181994A (en) 2021-01-18
SG11201610355PA (en) 2017-01-27
MA38860A (fr) 2016-02-17
KR20160029092A (ko) 2016-03-14
GB201410504D0 (en) 2014-07-30

Similar Documents

Publication Publication Date Title
MA38860B1 (fr) Cellule progénitrice immuno-modulatrice (imp)
CY1123142T1 (el) Βελτιωμενες μεθοδοι για την παραγωγη θετων κυτταρικων θεραπειων
SA518391159B1 (ar) مترافقات الألفة- قليلة النيوكليوتيد واستخداماتها
EA201592103A3 (ru) Способы и композиции для усиления cd4+ регуляторных t-клеток
EP3728563A4 (fr) Cellules effectrices immunes améliorées et leur utilisation
MX2023013342A (es) Celulas que expresan el receptor de antigeno quimerico (car) con funcion o expresion de tet reducida y metodos de uso de las mismas.
EA201790010A1 (ru) Гамма-дельта t-клетки и их применение
EP4620521A3 (fr) Procédés et compositions se rapportant à des chondrisomes provenant de cellules cultivées
MY185016A (en) Progenitor cells of mesodermal lineage
EP3729600A4 (fr) Équilibrage de cellules dans des batteries
EP3472305A4 (fr) Cellules treg génétiquement modifiées
MX2019003983A (es) Caspasas inducibles y metodos de uso.
MX2013004061A (es) Analogos de ciclosporina.
MY193650A (en) Extracellular matrix compositions
EA201890439A1 (ru) ИММУНООНКОЛОГИЧЕСКАЯ МЕЗОДЕРМАЛЬНАЯ КЛЕТКА-ПРЕДШЕСТВЕННИК (ioMP-КЛЕТКА)
TW201612308A (en) Collector architecture layout design
HUE047540T2 (hu) Javított allogén dendritikus sejtek rák kezelésében történõ alkalmazásra
DK3430037T3 (da) Transficerede t-celler og t-cellereceptorer til anvendelse i immunterapi mod cancere
PH12019502036A1 (en) Peptides and methods for the treatment of diabetes
EP3356524A4 (fr) Administration améliorée de gènes dans des cellules tueuses naturelles, des cellules souches hématopoïétiques et des macrophages
MX2013004062A (es) Analogos de ciclosporina.
EP3522936A4 (fr) Cellules modifiées non cytotoxiques et leur utilisation
CL2018001080A1 (es) Lixiviación en pilas.
EP3712256A4 (fr) Populations de cellules comprenant des cellules de mammifère cd31-positives, cd45-négatives, cd200-positives et utilisation correspondante
MX358340B (es) Extractos de tomillo silvestre y su uso.